New ADC trial data reshapes metastatic breast cancer care: why OS differs, where T-DXd fits, and SG’s frontline gains in TNBC.
Debbi-Ann Davidson, MSN, RN
Advertisement
Articles by Debbi-Ann Davidson, MSN, RN
Experts unpack new antibody-drug conjugate trial data, sequencing choices, and toxicity management reshaping metastatic breast cancer care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
3
3 Things You Should Know About Frontline and Maintenance Therapy for HER2+ Metastatic Breast Cancer
4
Exploring The Future of Artificial Intelligence and Thoracic Oncology
5